Segall Bryant & Hamill LLC grew its holdings in shares of Stryker Corporation (NYSE:SYK – Free Report) by 35.9% during the first quarter, Holdings Channel.com reports. The institutional investor owned 69,732 shares of the medical technology company’s stock after purchasing an additional 18,437 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Stryker were worth $22,913,000 at the end of the most recent quarter.
Several other hedge funds also recently modified their holdings of the stock. Godfrey Financial Associates Inc. bought a new position in Stryker during the fourth quarter worth $26,000. Sankala Group LLC acquired a new position in shares of Stryker during the fourth quarter valued at about $26,000. United Financial Planning Group LLC acquired a new position in shares of Stryker during the third quarter valued at about $27,000. Atlas Capital Advisors Inc. bought a new position in shares of Stryker during the 4th quarter worth about $27,000. Finally, DJE Kapital AG bought a new position in shares of Stryker during the 4th quarter worth about $28,000. Institutional investors own 77.09% of the company’s stock.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on SYK. Argus set a $370.00 target price on Stryker in a research report on Thursday, July 9th. Royal Bank Of Canada cut their price target on Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a report on Friday. UBS Group initiated coverage on Stryker in a research note on Tuesday. They issued a “buy” rating and a $400.00 price objective for the company. Leerink Partners lowered their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. Finally, Canaccord Genuity Group cut their target price on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, Stryker has an average rating of “Moderate Buy” and an average price target of $387.88.
Trending Headlines about Stryker
Here are the key news stories impacting Stryker this week:
- Positive Sentiment: Stryker reported second-quarter revenue of $6.59 billion, up 9.4% year over year, while adjusted EPS of $3.69 exceeded consensus estimates. Organic sales growth reached 9%, supported by strong demand for orthopedic, spinal and other medical devices. Stryker beats quarterly estimates on strong demand for medical devices
- Positive Sentiment: Management said it has regained momentum following the cyber disruption and resumed share repurchases. Its full-year guidance calls for 8.3% to 9.3% organic sales growth and adjusted EPS of $14.95 to $15.10. Stryker expects 2026 organic sales growth and adjusted EPS
- Positive Sentiment: JPMorgan maintained an “overweight” rating, although it reduced its price target to $350. Truist raised its target to $340 while retaining a “hold” rating, and BTIG continues to rate the shares “buy.”
- Neutral Sentiment: The updated guidance was narrower but remained broadly close to prior expectations and analyst forecasts. This suggests operational stability, but not a major upside revision that could drive a stronger investor reaction.
- Neutral Sentiment: Analyst opinion remains generally constructive, with no recent sell ratings cited and a six-month median price target of $385, though target reductions indicate some caution regarding valuation or near-term upside.
- Negative Sentiment: The main pressure on SYK appears to be an expectations reset: despite the earnings beat, investors had anticipated a more substantial increase to full-year guidance after the cyberattack recovery. SYK falls despite Q2 earnings beat
- Negative Sentiment: Reported insider activity has been heavily weighted toward selling, with no purchases and substantial sales over the past six months. This may add to investor concerns about valuation and management confidence, although the trades do not necessarily reflect current operating performance.
Stryker Stock Down 6.2%
Stryker stock opened at $326.41 on Friday. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $401.99. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The firm’s 50-day simple moving average is $317.28 and its 200 day simple moving average is $334.92. The stock has a market cap of $125.13 billion, a PE ratio of 33.82, a price-to-earnings-growth ratio of 2.23 and a beta of 0.77.
Stryker (NYSE:SYK – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 24.06% and a net margin of 14.43%.Stryker’s revenue was up 9.4% on a year-over-year basis. During the same period last year, the business posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts predict that Stryker Corporation will post 14.99 EPS for the current fiscal year.
Stryker Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th were given a $0.88 dividend. The ex-dividend date of this dividend was Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is currently 40.74%.
Insider Buying and Selling at Stryker
In related news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares in the company, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 323,264 shares of company stock worth $100,659,489 over the last three months. 4.60% of the stock is currently owned by insiders.
Stryker Profile
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Featured Stories
- Five stocks we like better than Stryker
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
-etf-logo-1200x675.png){kind=logo}
